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Depression and anxiety are common conditions representing a 
large global health burden, with depression the largest cause of 
disability globally (World Health Organization, 2017). Depression 
and anxiety are overlapping syndromes that commonly occur 
together (Fava et al., 2004; Kessler et al., 1996) and the patient 
burden and complexity increases when both are present 
(McLaughlin et al., 2006). Comorbid anxiety in depression is 
associated with poorer chances of response to treatment, increased 
severity of depression (Nutt, 1999) and increased chance of sui-
cide (Fawcett, 1988). The majority of patients with anxiety and 
depression are managed in a primary care setting, with antidepres-
sants prescriptions increasingly yearly, with 67.5 million antide-
pressant prescriptions in the UK in 2017 (ONS, 2018).
There is evidence for the effectiveness of mirtazapine 
(Neuroscience based Nomenclature (NbN): Norepinephrine, 
Serotonin, Receptor antagonist) in several anxiety disorders such 
as generalized anxiety disorder (GAD) (Gambi et al., 2005), panic 
disorder (Ribeiro et al., 2001), obsessive compulsive disorder 
(Koran et al., 2005; Pallanti et al., 2004), post-traumatic stress 
disorder (Davidson et al., 2003) and social anxiety disorder 
(Muehlbacher et al., 2005; Schutters et al., 2010). Mirtazapine has 
also been found to have important actions on relieving anxiety 
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Background: There is a lack of evidence to guide treatment of comorbid depression and anxiety. Preliminary evidence suggests mirtazapine may be 
effective in treating patients with both depression and anxiety symptoms.
Methods: We undertook a secondary analysis of mirtazapine (MIR): a placebo-controlled trial of the addition of mirtazapine to a selective serotonin 
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into three groups by baseline generalized anxiety disorder score (GAD-7): severe (GAD-7 ⩾ 16), moderate (GAD-7 = 11–15), no/mild (GAD-7 ⩽ 10). 
We used linear regression including likelihood-ratio testing of interaction terms to assess how baseline anxiety altered the response of participants to 
mirtazapine as measured by 12-week GAD-7 and Beck Depression Inventory II (BDI-II) scores.
Results: Baseline generalized anxiety moderated mirtazapine’s effect as measured by GAD-7 (p = 0.041) and BDI-II (p = 0.088) at 12 weeks. 
Participants with severe generalized anxiety receiving mirtazapine had lower 12-week GAD-7 score (adjusted difference between means (ADM) −2.82, 
95% confidence interval (CI) −0.69 to −4.95) and larger decreases in BDI-II score (ADM −6.36, 95% CI −1.60 to −10.84) than placebo. Conversely, 
there was no anxiolytic benefit (ADM 0.28, 95% CI −1.05 to 1.60) or antidepressant benefit (ADM −0.17, 95% CI −3.02 to 2.68) compared with placebo 
in those with no/mild generalized anxiety.
Conclusions: These findings extend the evidence for the effectiveness of mirtazapine to reduce generalized anxiety in TRD in primary care. These 
results may inform targeted prescribing in depression based on concurrent anxiety symptoms, although these conclusions are constrained by the post-
hoc nature of this analysis.
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symptoms in patients with comorbid anxiety and depression in a 
meta-analysis (Fawcett and Barkin, 1998), while a small study has 
shown promising anti-depressant efficacy in dual-diagnosis anxi-
ety and depression disorder (Goodnick et al., 1999).
These trials did not, however, examine the relative effect of 
mirtazapine on those with and without anxiety in the same patient 
cohort. Furthermore, they were not conducted in a primary care 
setting, where most patients with anxiety and depression are 
managed.
There is a lack of evidence to inform guidelines around treat-
ing depression with comorbid anxiety. Most evidence-informed 
guidelines such as National Institute for Health and Clinical 
Excellence (NICE) guidelines do not offer any specific advice on 
treating comorbid psychiatric conditions or preferred augmenta-
tion agents (NICE, 2020). This issue is recognized by a recent 
guideline from the French Association for Biological Psychiatry: 
“Although the issue of comorbidity is recognized by evidence-
based guidelines, few specific recommendations are provided 
regarding acute treatment with antidepressant drugs”. This guide-
line, based on expert consensus, suggests a selective serotonin 
reuptake inhibitor (SSRI, NbN: SERT) or serotonin norepineph-
rine reuptake inhibitor (SNRI, NbN: SERT and NET) as first-line 
therapy for depression with any comorbid anxiety disorder, with 
mirtazapine recommended as a possible second-line agent 
(Bennabi et al., 2019).
The mirtazapine (MIR) trial (Kessler et al., 2018) investigated 
the effectiveness of the addition of mirtazapine to an SSRI or 
SNRI in 480 patients with treatment-resistant depression (TRD) 
recruited from primary care. Treatment-resistance was defined 
pragmatically as failure to respond to at least six weeks of an 
SSRI/SNRI at an adequate dose; in the event, 90% of patients in 
MIR had been on antidepressants for more than six months. The 
MIR trial did not find evidence of a meaningful clinical difference 
between Beck Depression Inventory score (BDI-II) scores at 
12 weeks for mirtazapine compared with placebo (adjusted differ-
ence between means (ADM) −1.83, 95% confidence interval (CI) 
−3.92 to 0.27, primary outcome). It did, however, find a small 
difference in GAD-7 scores at 12 weeks for mirtazapine compared 
with placebo (ADM 0.98, 95% CI 0.03 to 1.93, secondary out-
come), although it is not clear whether this is clinically meaning-
ful. GAD-7 is a questionnaire which captures the features of GAD 
– a syndrome with the core symptoms of excessive, difficult to 
control and disruptive anxiety and worry with associated features 
such as restlessness and lack of sleep (American Psychiatric 
Association, 2013). Similarly PANDA, a recent primary care trial 
of sertraline for depression, showed clear improvements in gener-
alized anxiety, despite less convincing evidence of a superior anti-
depressant effect compared with placebo (Lewis et al., 2019).
The frequent comorbidity of depression and anxiety means 
targeted prescribing for this group is a potentially valuable objec-
tive. The MIR participants had high levels of generalized anxiety, 
with 48.6% scoring greater than 10 on GAD-7 at baseline, the 
normal cut-off point for screening for GAD (Spitzer et al., 2006). 
This is consistent with the previous research finding that 46% of 
those with depression have moderate to severe anxiety (Fava 
et al., 2004). The MIR trial thus represents an important resource 
to examine a possible rationale for targeted prescribing in a com-
mon and difficult to manage cohort. Using data from the MIR 
trial, we aimed to investigate whether there was a differential 
effect on generalized anxiety and depression symptoms at 12 
weeks according to baseline severity of generalized anxiety. 
Because there is evidence of mirtazapine’s effectiveness in anxi-
ety disorders (Baldwin et al., 2014; Katzman et al., 2014) and 
preliminary evidence of its effectiveness in depression with anxi-
ety symptoms (Fawcett and Barkin, 1998; Goodnick et al., 1999), 
we hypothesized that mirtazapine may be more effective in indi-




The MIR study (Kessler et al., 2018) was a multicentre pragmatic 
randomized, placebo-controlled trial recruiting 480 adults aged 18 
years or more from general practices within four sites in England. 
Participants fulfilled International Classification of Disease-10 
(ICD-10) criteria for depression with an initial BDI-II score of >14, 
despite using an SSRI or SNRI for at least six weeks. Patients with 
dementia, bipolar disorder, psychosis or any substance misuse dis-
order were excluded. Participants were identified through interro-
gation of GP records for those receiving antidepressant prescriptions 
on repeat or recruited opportunistically during GP consultations. 
These patients were then screened according to inclusion and exclu-
sion criteria and invited to join the study.
In MIR, 241 participants were randomized to mirtazapine and 
239 to placebo, both given in addition to usual SSRI or SNRI 
treatment. Participants were stratified by centre and minimized 
by baseline BDI-II score (Beck et al., 1996), sex and current psy-
chological therapy. The primary outcome was BDI-II score at 
12 weeks, with the GAD-7 score at 12 weeks a secondary out-
come measure.
Full details of the MIR trial methodology are available else-
where (Kessler et al., 2018). The protocol for the original trial 
was pre-published (Tallon et al., 2016).
Stratification
This analysis was a hypothesis-driven secondary analysis using data 
from the MIR trial. Participants were stratified into groups based on 
their initial depression and generalized anxiety scores. To ensure 
clinically relevant categories, BDI and GAD-7 were stratified 
according to the scoring criteria used in validation studies (Beck et 
al., 1996; Spitzer et al., 2006). We wanted to optimize power of our 
analysis and so aimed to minimize the number of categories to pre-
serve the ability of interaction terms to find differences. Previous 
research suggested that 10 was an optimal cut-off to ensure optimal 
sensitivity and specificity for diagnosis of generalized anxiety 
(Spitzer et al., 2006). Therefore, we combined the GAD-7 categories 
of 0–5 and 6–10 to provide our low/no anxiety baseline group. 
Resulting participants were stratified into three anxiety groups: mild 
generalized anxiety symptoms (GAD-7 ⩽10, n = 245), moderate 
generalized anxiety symptoms (GAD-7 11–15, n = 133) and severe 
generalized anxiety symptoms (GAD-7 ⩾16, n = 99). Three partici-
pants had no baseline GAD-7 measure and, thus, could not be 
included. BDI-II was stratified according to its standard clinical 
groupings: mild depression (BDI-II 14–19, n = 69), moderate 
depression (BDI-II 20–28, n = 138) and severe depression (BDI-II 
>29, n = 273) (Beck et al., 1996).
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Statistical analysis
Chi-square tests were used to examine differences in baseline 
characteristics between groups stratified according to GAD-7 
scores as described above. Univariable regression was employed 
likewise for continuous measures. Three categorical baseline 
variables were found to differ across generalized anxiety severity 
strata above our threshold level for inclusion (p < 0.05): educa-
tion level, suicidal ideation and financial situation.
We used multivariable linear regression models to compare the 
mirtazapine and placebo groups, adjusting for stratification and 
minimization variables and the corresponding baseline value. This 
approach was based upon the model used in MIR. In the models 
examining GAD-7 at follow-up, we adjusted for baseline GAD-7 
using the three-level categorical measure. We used likelihood ratio 
tests of an interaction term between treatment group and baseline 
anxiety strata to model the effect that baseline generalized anxiety 
had on each outcome as described in the below section.
We ran the analysis with two models. The primary model was 
identical to the original MIR analysis to ensure comparability. 
The second, fully adjusted model additionally adjusted for educa-
tion level, suicidal ideation and financial situation – the three 
baseline variables that differed by anxiety strata. All of these 
models adjusted for baseline depression level.
We used categorial variables in our interaction term as we 
decided that these would enable any findings to be easily inter-
pretable and relevant to clinical practice.
To check if our results were specific to severe generalized anxi-
ety rather than general symptom severity, we repeated all the linear 
regression models described above, substituting baseline depres-
sion group for baseline generalized anxiety group in the interaction 
term to see if the response to mirtazapine compared with placebo 
was moderated by increasingly severe baseline depression.
All analyses were performed with STATA v15.
Sensitivity analysis
As a sensitivity analysis, we ran our main models with logged 
values of the baseline and 12-week symptom scale scores. This 
enables a regression model assessing a ratio of baseline to 12-week 
score and, thus, the percentage change in symptoms to assess if 
our results still applied in this scenario. We also ran a missing 
imputation using chained equations (MICE) regression model on 
our data to check for effects of missing data as in the original MIR 
study. This model was run with 30 iterations, as guided by the 
fraction of missing information on the initial model.
Outcomes
Primary outcomes of interest were 12-week generalized anxiety 
and depression symptoms (GAD-7 and BDI-II) with mirtazapine 
compared with placebo. We also examined response as assessed 
by GAD-7 and BDI-II (defined as at least a 50% decrease in 
score relative to baseline) as although this measure is less pow-
ered this was a secondary outcome in the original MIR analysis 
and an easier measure to interpret clinically.
To further explore any benefits, we also assessed the effect gen-
eralized anxiety had on the other MIR secondary outcomes: PHQ-9 
(Patient Health Questionairre-9), social and physical functioning 
(SF-12 mental subscale) and quality of life scores (EQ-5D-5L).
Results
Baseline characteristics
At baseline, 477/480 (99.4%) of participants in the MIR study 
had a GAD-7 measurement. For analysis purpose, these individu-
als were then stratified into three groups: mild generalized anxi-
ety symptoms (GAD-7 ⩽10, n = 245), moderate generalized 
anxiety symptoms (GAD-7 11–15, n = 133) and severe general-
ized anxiety symptoms (GAD-7 ⩾16, n = 99).
There was no major differences in proportions allocated to 
mirtazapine and placebo across the three anxiety stratification 
groups. In addition, there was no evidence of such differences in 
terms of sex (p = 0.66), age (p = 0.12), ethnicity (p = 0.19) or 
currently being in receipt of psychological treatment (p = 0.30). 
Groups with higher generalized anxiety had poorer educational 
attainment (p < 0.01), reported worse financial well-being (p < 
0.01) and more suicidal ideation (p < 0.01). The higher general-
ized anxiety groups also had higher baseline depression (p < 
0.01) and lower quality of life scores (p < 0.01) (Table 1).
Missing data
Since 49 participants had missing end-point values and three par-
ticipants were missing baseline anxiety levels, we analysed 428 
out of 480 participants (89.2%). Missing data were balanced 
between the two randomized groups (Placebo 22/239, Mirtazapine 
30/241, χ2(1) = 1.31, p = 0.25). There was a suggestion of 
slightly more missing data in the higher severity anxiety strata 
(χ2(2) = 4.97, p = 0.083). Full details of the breakdown of miss-
ing data can be found in Supplementary Table 1.
Moderation of GAD-7 at 12 weeks by severity 
of generalized anxiety
The original MIR analysis found a small overall benefit in reducing 
generalized anxiety at 12 weeks for mirtazapine compared with pla-
cebo (ADM −0.98, 95% CI −0.03 to −1.93, p = 0.04). Here we 
found evidence that the anxiolytic benefit of mirtazapine at 12 weeks 
was moderated by baseline GAD-7 group (likelihood ratio test for 
interaction p = 0.041). A load-dependent effect of generalized anxi-
ety on the benefit of mirtazapine over placebo was observed with 
those most anxious obtaining the highest benefit (Table 2, Figure 1). 
We similarly found evidence that GAD-7 response rate (⩾50% 
reduction in GAD-7 scores at 12 weeks) was moderated by baseline 
GAD-7 scores (likelihood ratio p = 0.023). Mirtazapine had a higher 
GAD-7 response rate compared with placebo in both those with 
moderate and severe generalized anxiety. Our fully adjusted regres-
sion models, which accounted for baseline differences in group char-
acteristics, showed similar differences (Supplementary Table 2).
Moderation of BDI-II at 12 weeks by severity 
of generalized anxiety
The original MIR analysis did not find a clinically meaningful 
benefit in depressive symptoms for mirtazapine compared with 
placebo at 12 weeks (ADM −1.83, 95% CI −3.92 to 0.27). In the 
present research, we found weak evidence for a beneficial effect 
moderated by baseline GAD-7 scores by assessing the interaction 
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term (likelihood ratio p = 0.088). The bulk of this effect was 
accounted for by a large increase in the antidepressant effect of 
mirtazapine in the most anxious (ADM −6.11, 95% CI −1.51 to 
−10.71) (Table 2, Figure 1). In contrast, there was no statistical 
evidence that baseline generalized anxiety moderated BDI-II 
response rate (50% decrease in BDI symptoms at 12 weeks) 
(likelihood ratio p = 0.254), although the descriptive statistics 
are in keeping with more improvement in those who are most 
anxious (OR 2.80, 95% CI 1.08 to 7.28) (Table 2).
Unadjusted change in GAD-7 and BDI scores with response 
rates by anxiety group are shown in full in Table 3.
Moderation of secondary outcomes by 
severity of generalized anxiety
We found moderating effects of anxiety group on depressive symp-
toms measured using the PHQ-9 (likelihood ratio: p = 0.056) and 
scores on the SF-12 mental subscale (likelihood ratio: p = 0.065) but 
not quality of life scores (EQ-5D-5L) (likelihood ratio: p = 0.684).
Results adjusted for variables imbalanced between anxiety 
strata were very similar (data not shown).
Sensitivity analysis
Sensitivity analyses were run using logged outcomes for continu-
ous symptom scales. These analyses showed results that were in 
line with our main regression models (Supplementary Table 3). 
Similarly, regression models run with MICE analysis to examine 
Table 1. Participant characteristics by generalized anxiety severity group.
GAD-7 ⩽ 10 mild/
minimal generalized 
anxiety
GAD-7 11–15  
moderate generalized 
anxiety






p-value with statistical 
test results
Total in each stratum 245 133 99 477 -
Allocation
Allocated to mirtazapine: n (%) 117 (47.8%) 69 (51.9%) 52 (52.5%) 238 (49.9%) N/A†
Socio-demographic variables
Sex: n (%) Female 174 (71.0%) 90 (67.7%) 66 (66.7%) 330 (69.2%) p = 0.662 χ2(2) = 0.82
In receipt of psychological 
therapy: n (%)
Yes 27 (11.0%) 18 (13.5%) 17 (17.2%) 62 (13.0%) p = 0.300 χ2(2) = 2.41
Age (years): mean (SD) 51.2 (13.0) 48.4 (13.0) 49.6 (13.8) 50.1 (13.2) p = 0.124 F(2) = 2.10
Ethnic group: n (%) White 240 (98.0%) 131 (98.5%) 94 (94.9%) 465 (97.5%) p = 0.185 χ2(2) = 3.37
 Non-White 5 (2.0%) 2 (1.5%) 5 (5.1%) 12 (2.5%)  
Financial well-being: n (%) “Comfortable/
OK”
133 (54.3%) 51 (38.3%) 39 (39.4%) 223 (46.8%) p = 0.003 χ2(2) = 11.51
 “Just about 
getting by or 
worse”
112 (45.7%) 82 (61.7%) 60 (60.6%) 254 (53.2%)  
Baseline severity variables
GAD-7 score: mean (SD) 7.1 (2.2) 12.8 (1.3) 18.2 (1.8) 11.0 (4.8) N/A
BDI-II score: mean (SD) 26.8 (7.9) 32.2 (9.3) 39.7 (9.0) 31.0 (9.9) p < 0.001 F(2) = 81.52
SF-12 mental subscale : 
mean (SD)
32.5 (8.9) 26.8 (8.7) 21.5 (8.3) 28.6 (9.7) p < 0.001 F(2) = 57.92
CIS-R score: mean (SD) 23.6 (7.1) 29.3 (6.5) 35.3 (6.9) 27.6 (8.3) p < 0.001 F(2) = 105.56
Suicidal ideation: n (%) Suicidal 
thoughts
62 (25.3%) 59 (44.4%) 53 (53.5%) 174 (36.5%) p < 0.001 χ2(4) = 2.23
†There is no need for statistical testing across randomization groups.
SD: standard deviation.
effects of missing data showed substantively similar results to the 
original model (Supplementary Table 4).
Moderation of mirtazapine effects by severity 
of depression
There was no evidence that baseline depression (as measured by 
the BDI-II) moderated the effect of mirtazapine compared with 
placebo in terms of its effect on GAD-7 (likelihood ratio p = 
0.86), response on the GAD-7 response (likelihood ratio p = 
0.20), improvement in BDI-II (likelihood ratio p = 0.66) or 
response on the BDI-II (likelihood ratio p = 0.63). Results 
adjusted for variables imbalanced between anxiety strata were 
very similar (data not shown).
Discussion
Our analysis found that the reduction in generalized anxiety 
symptoms (GAD-7) at 12 weeks after addition of mirtazapine to 
an SSRI or SNRI in TRD was moderated by baseline anxiety. 
Furthermore, there was weak evidence that baseline generalized 
anxiety moderated reduction in depression as assessed by BDI-II 
scores at 12 weeks. Additional analyses also showed some evi-
dence that baseline generalized anxiety moderated change in 
depression as measured by PHQ-9, and social functioning (SF-
12) but not quality of life scores (EQ-5D-5L).
The benefit of mirtazapine over placebo was the most pro-
nounced in people with severe generalized anxiety (GAD-7 
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⩾16). In this group, the benefit was apparent in BDI-II, PHQ-9 
and SF-12 scores as well as GAD-7. Conversely, in the group 
with minimal/mild generalized anxiety (GAD-7 ⩽10), estimates 
of difference between adding in mirtazapine versus placebo were 
close to zero across all relevant outcome measures (BDI-II, 
GAD-7, PHQ-9, SF-12 and EQ-5D-5L) despite a larger group 
size of 227. This suggests that in the TRD group with mild gen-
eralized anxiety, there appears to be little benefit for adding in 
mirtazapine to an SSRI/SNRI. This group represents around half 
the study population.
There was no evidence of moderation by baseline depression 
severity as measured by the BDI-II. However, those with severe 
generalized anxiety symptoms had, on average, severe depres-
sion on the BDI-II, while those with low levels of generalized 
anxiety had only moderate severity depression. While our results 
do not support mirtazapine being more effective than placebo in 
those with greater severity of depressive symptoms in isolation, 
it is possible that its benefits are more apparent in patients expe-
riencing a greater severity of illness expressed as a combination 
of depressive and anxiety symptoms.
In the most anxious group (GAD-7 ⩾16), depression scores 
as assessed by BDI-II were 6.11 lower than the placebo group on 
average. This difference is sizeable and likely to be clinically 
important. Meanwhile, the improvement of 2.8 points on GAD-7 
compared with placebo found in the most anxious group in our 
analysis compares favourably to the improvement found in 
PANDA of sertraline over placebo (1.3) (Lewis et al., 2019). 
Furthermore, recent unpublished work based on the PANDA 
cohort suggests that an improvement of 1.5 on the GAD-7 is a 
clinically meaningful change whereby patients are likely to feel 
better (Kounali et al., 2020), a threshold our findings exceed. 
However, the population in PANDA were not treatment-resistant, 
and a higher threshold for meaningful clinical improvement 
might apply to the MIR trial population (Button et al., 2015).
We found that mirtazapine appears to decrease depressive 
symptoms and improve mental-health-related social functioning 
in people with more severe generalized anxiety, but not in those 
without generalized anxiety, in the context of a trial that did not 
find overall treatment group differences (Kessler et al., 2018). A 
possible explanation for this is that augmentation of mirtazapine 
in depressed patients with comorbid generalized anxiety helps 
























































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Difference in depression and generalized anxiety using 
mirtazapine compared to placebo, by baseline generalized anxiety. 
Bars represent 95% confidence intervals. Lower numbers indicate lower 
symptom severity scores at end of treatment – that is, more benefit 
from use of mirtazapine.
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depressive symptoms and better general functioning. This was 
observed in the PANDA trial where decreases in anxiety levels 
were seen at six weeks, while decreases in depressive symptoms 
took 12 weeks to occur (Salaminios et al., 2017). Unfortunately, 
the MIR trial did not measure GAD-7 levels at six weeks, so we 
were unable to test this hypothesis in this study.
Strengths and limitations
Limitations of this paper include that this was an unplanned sec-
ondary analysis of a trial, which can be susceptible to hypothesiz-
ing after results are known (Kerr, 1998) and multiple testing. 
However, previous literature has explored mirtazapine’s effect in 
anxiety (Fawcett and Barkin, 1998; Kim et al., 2011) and this led 
to the hypothesis-driven nature of this analysis of a single moder-
ating factor.
The post-hoc nature of the analysis means that the trial was 
not originally designed to examine the relationships explored in 
this paper and, hence, was underpowered. This explains the wide 
confidence intervals found in our analysis, which cover differ-
ences that may or may not be clinically relevant.
Participants were recruited based on depression diagnosis and 
high BDI-II scores. A sizeable proportion of the participants, 
therefore, had lower generalized anxiety scores as assessed by 
GAD-7. These participants have less scope for improving anxiety 
symptoms due to a floor effect. However, although this effect 
may contribute to the observed interaction when examining 
GAD-7 scores, it is not sufficient to explain the observed moder-
ating effects of baseline generalized anxiety on PHQ-9, SF-12 or 
BDI-II scores, even when adjusting for baseline depression.
The strengths of this analysis are that this large, randomized 
controlled trial was pragmatically recruited, with a definition of 
TRD easy to operationalize in a primary care setting. Furthermore, 
this tests the treatment in the setting where it is most used: pri-
mary care. Additionally, our participants had a range of general-
ized anxiety symptoms representative of findings in previous 
research (Fava et al., 2004). These factors make our findings 
more generalizable.
Furthermore, our regression analyses adjusted for baseline 
differences including all the minimizing factors involved in ran-
domization and baseline depression scores. Additionally, our 
analyses survived last observation carried forward, log transfor-
mation and further adjustment for other baseline differences 
across baseline anxiety stratum. This suggests a robust observed 
effect.
Another strength is the large size of the trial, which meant 
there were substantial numbers in each sub-group, allowing for 
direct comparison of effectiveness across anxiety groups in one 
trial – which has not previously been examined. Furthermore, 
unlike previous evidence (Fawcett and Barkin, 1998) that used 
subscales of depression scores to assess anxiety, MIR examined 
generalized anxiety with GAD-7. This is a specific, well-vali-
dated measure used widely in screening for GAD, with a cut-off 
score of 10 on GAD-7, having a 89% sensitivity and 82% speci-
ficity (Spitzer et al., 2006). The effects found here would be clini-
cally important if they were to be replicated.
Implications
Clarifying effective treatment for patients with treatment-resist-
ance in primary care is key, as these patients are a common group 
that suffer from poorer quality of life, are harder to manage and 
utilize substantial healthcare resources (Mrazek et al., 2014). 
When depression and anxiety symptoms co-occur, they represent 
a more severe end of the population of depressed people 
(Pandarakalam, 2018). This is reflected in the baseline character-
istics of participants in our high generalized anxiety group 
(GAD-7 ⩾16) who had higher baseline depression, rates of sui-
cidal ideation and rates of struggling financially in addition to 
lower quality of life measures.
These results add support to existing evidence that mirtazap-
ine is a useful treatment in managing generalized anxiety in those 
with depression (Fawcett and Barkin, 1998). Additionally, this 
analysis suggests the possibility that this use of mirtazapine in 
those with severe generalized anxiety may improve both depres-
sive symptoms and social functioning. This result was achieved 
by the addition of mirtazapine to an SSRI or SNRI, a strategy 
previous trials did not examine. These findings suggest a possible 
path to selectively targeting the addition of mirtazapine based on 
comorbid generalized anxiety symptoms when first-line treat-
ment fails. This is in line with existing expert-consensus-based 
guidance on the use of mirtazapine in those with anxiety-pre-
dominant depression (Bennabi et al., 2019).
Conversely, these findings did not find any evidence for add-
ing in mirtazapine in those without generalized anxiety symp-
toms, who have failed to respond to first-line antidepressant 
therapy. This is important, given the increase in prescriptions of 
antidepressants, to identify groups where antidepressants fail to 
work, in addition to those in whom they might be effective (ONS, 
2018).
Table 3. Raw score changes and response rates.




Severe generalized anxiety 
(GAD-7 ⩾16)












Mean change in GAD-7 from baseline to 12 weeks (SD) 1.46 (4.42) 1.37 (4.72) 4.05 (4.96) 6.02 (5.02) 4.61 (5.29) 7.70 (6.72)
GAD-7 response rate 36.7% 32.5% 32.8% 55.1% 19.1% 36.5%
Mean change in BDI-II from baseline to 12 weeks (SD) 10.71 (10.17) 10.77 (10.87) 11.39 (12.73) 13.81 (10.47) 10.65 (13.15) 16.76 (16.67)
BDI-II response rate 40.0% 42.1% 37.5% 48.3% 22.0% 43.5%
This table shows the raw mean change in GAD-7 and BDI-II scores and response rate for each sub-stratum.
SD: standard deviation.
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Further research
The results found here should be further explored. Obtaining 
individual-patient-level data in previous trials for mirtazapine in 
TRD would help determine if the effects found here can be repli-
cated. A formal study to assess the benefits of mirtazapine in 
treating TRD with severe symptoms of generalized anxiety might 
then be warranted.
Conclusion
In this secondary analysis, the addition of mirtazapine was more 
effective at treating generalized anxiety than placebo in patients 
with TRD and severe anxiety symptoms. Mirtazapine may also 
be more effective at treating depressive symptoms and improving 
social functioning in those who have higher levels of anxiety. 
Conversely, there appears to be little clinical utility in adding 
mirtazapine in those without any concurrent anxiety. This should 
be formally assessed in trials in the future but may represent a 
strategy for stratifying treatment of resistant depression depend-
ing on symptom subtype.
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